Unknown PHASE2 INTERVENTIONAL 1-arm NCT04172805

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

A Single-arm, Open, Phase II Study of Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sponsor: Sun Yat-sen University

Conditions Sarcoma,Soft Tissue

Interventions anlotinib and toripalimab

Updated 10 times since 2019 Last updated: Apr 11, 2023 Started: Mar 13, 2020 Primary completion: Mar 1, 2024 Completion: May 15, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Sarcoma,Soft Tissue and is currently ongoing. Sun Yat-sen University leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

May 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — May 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Sep 2022 — May 2023 [monthly]

Recruiting PHASE2

▶ Show 5 earlier versions

Dec 2021 — Sep 2022 [monthly]

Recruiting PHASE2
Jan 2021 — Dec 2021 [monthly]

Recruiting PHASE2
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2020 — Nov 2020 [monthly]

Not Yet Recruiting PHASE2
Dec 2019 — Apr 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China